Search clinical trials for: TroVax® (Immunological Vaccine Therapy)

Total 7688 results

Emergent BioSolutions

Completed

Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults

Smallpox

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Purified Vero Rabies Vaccine and Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post-exposure Regimen

Rabies

United States
Sanofi Pasteur, a Sanofi Company

Completed

Comparison of Purified Vero Rabies Vaccine, Serum Free With Human Diploid Cell Vaccine in Pre-exposure Use

Rabies

United States
Emergent BioSolutions

Completed

Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination

Smallpox

United States
The Methodist Hospital Research Institute
Oxford BioMedica

Completed

Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer

Carcinoma, Renal Cell

United States
Sanofi Pasteur, a Sanofi Company

Completed

Purified Vero Rabies Vaccine-Serum Free Compared to Human Diploid Cell Vaccine in a Pre-exposure Prophylaxis Regimen

Rabies

Philippines
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Fractional Doses of IPV Intradermally vs Full Doses Intramuscularly

Poliomyelitis

Philippines
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen to Children and Adults and as Single Booster Dose to a Subset of Adults (VRV12)

Rabies (Healthy Volunteers)

Thailand
University College, London
Cancer Research UK; Oxford BioMedica

Completed

The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer (TRIOC)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Study of IMOVAX POLIO® Subcutaneous as a Booster Vaccine in Pre-school Age Children in Japan

Poliomyelitis | Polio

Japan
Sanofi Pasteur, a Sanofi Company

Completed

Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults

Smallpox

United States
U.S. Army Medical Research and Development Command
GlaxoSmithKline; United States Agency for International Development (USAID); Walter... and other collaborators

Completed

Phase 1 Trial of a Malaria Vaccine in Young Kenyan Children

Plasmodium Falciparum Malaria

Kenya
CSL Behring
CSL Plasma

Completed

Rabies Immune Plasma Booster Study

Rabies

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Withdrawn

S0348 Vaccine Therapy in Treating Patients With Stage IIIB or Stage IV Breast Cancer in Remission

Breast Cancer
Sanofi Pasteur, a Sanofi Company

Completed

Safety of Imovax Polio in Chinese Infants and Children

Poliomyelitis

China
Emory University
International AIDS Vaccine Initiative; Zambia-Emory HIV Research Project

Completed

Zambia SiVET MMR Tdap-IPV (SiVET)

High Risk for HIV

Zambia
Vaxine Pty Ltd
Central Adelaide Local Health Network Incorporated

Completed

Monovalent Recombinant COVID19 Vaccine (COVAX19)

Coronavirus Infection | COVID

Australia
Seqirus

Completed

A Study to Assess the Immunogenicity and Safety of CSL's 2012/2013 Formulation of Enzira® Vaccine in Healthy Volunteers

Influenza, Human

United Kingdom
Seqirus

Completed

A Study to Assess the Immunogenicity and Safety of CSL's 2013/2014 Formulation of Enzira® Vaccine in Healthy Volunteers

Influenza, Human

United Kingdom
PATH
Centers for Disease Control and Prevention; Institut Pasteur; Institut de Recherche...

Completed

Inactivated Influenza Vaccine Effectiveness in Tropical Africa

Influenza

Senegal
Wayne Sullender, M.D.
All India Institute of Medical Sciences, New Delhi; Centers for Disease Control...

Completed

Direct and Indirect Protection by Influenza Vaccine Given to Children in India

Influenza

India
Sanofi Pasteur, a Sanofi Company

Terminated

Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination

Smallpox

United States
Green Cross Corporation

Unknown

A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy Adults

Whooping Cough | Tetanus | Diphtheria

Korea, Republic of
University Health Network, Toronto

Completed

Adjuvanted Influenza Vaccine in Stem Cell Transplant

Transplantation | Influenza Vaccines
CHU de Quebec-Universite Laval
GlaxoSmithKline

Unknown

MMR and MMRV Vaccines: Effect of Age at First Dose on Safety and Immunogenicity of the Measles Component.

Measles
Sanofi Pasteur, a Sanofi Company

Completed

Phase IV Trial to Determine the Safety and Immunogenicity of the WHO Formulation of the 2006-2007 Fluzone® Vaccine

Influenza

United States
DynPort Vaccine Company LLC, A GDIT Company

Completed

Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation of a Cell-Cultured Smallpox Vaccine Compared to Dryvax®

Smallpox

United States
Green Cross Corporation

Unknown

Safety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) Vaccine

Whooping Cough | Tetanus | Diphtheria

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults

Rabies (Healthy Volunteers)

France
Centre Hospitalier Universitaire Saint Pierre
Université Libre de Bruxelles

Not yet recruiting

Maternal Determinants of Infant Immunity to Pertussis (MADI-02)

Pertussis | Maternal-Fetal Relations | Vaccination; Infection | Immunoglobulins

Belgium
St George's, University of London

Unknown

Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Population (ProPositive)

HIV Infections | Hiv | Meningitis, Meningococcal

United Kingdom
Children's Hospital Medical Center, Cincinnati
Centers for Disease Control and Prevention

Completed

Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot Study

Intussusception | Rotavirus Infections

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers

Dengue | Dengue Hemorrhagic Fever

Mexico
City of Hope Medical Center
National Cancer Institute (NCI); Diavax Biosciences

Active, not recruiting

Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant

Hodgkin Lymphoma | Myelofibrosis | Lymphoblastic Lymphoma | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Lymphadenopathy | Myeloproliferative Neoplasm | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Acute Myeloid Leukemia in Remission | Accelerated Phase... and other conditions

United States
City of Hope Medical Center

Withdrawn

Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

Hodgkin Lymphoma | Myelofibrosis | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Hematopoietic Cell Transplantation Recipient | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Acute Myeloid Leukemia in Remission | Accelerated... and other conditions

United States
Helsinki University Central Hospital
University of Helsinki

Recruiting

Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines

Cholera | Typhoid Fever | Vaccine-Preventable Diseases

Finland
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults

Influenza

United States
Walvax Biotechnology Co., Ltd.

Completed

A Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine in Healthy Subjects Aged 2-10 Years

Neisseria Meningitides Meningitis

Mali
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Imovax Polio in Chinese Infants Compared to Local OPV

Poliomyelitis | Polio

China
University Hospital, Ghent

Completed

Phase 1 Study on the Safety and Reactogenicity of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) Given Intramuscularly Compared to Standard Trivalent Inactivated Poliovirus Vaccine (IPV) in Healthy Adults (IPV-004)

Poliomyelitis

Belgium
PATH

Completed

Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge Study in Healthy Adults

Polio

Belgium
HaEmek Medical Center, Israel

Unknown

Safety and Tolerability of Herpes Zoster Vaccine Rheumatologic Patients

Herpes Zoster

Israel
Sanofi Pasteur, a Sanofi Company

Completed

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2022/23

Influenza (Healthy Volunteers)

Germany, Finland
Sanofi

Completed

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2023/24

Influenza Immunization (Healthy Volunteers)

Finland, Germany
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID); National Institutes...

Completed

The Effects of Attenuated Versus Inactivated Flu Vaccine in Twin Sets (FLU-TW)

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2021/22

Influenza (Healthy Volunteers)

Germany, Finland
ModernaTX, Inc.

Active, not recruiting

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US

Healthy Volunteers (Meningococcal Infection)

United States, Puerto Rico
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)

Papillomavirus Infections | Coronavirus Disease (COVID-19)

United States
Bavarian Nordic

Completed

Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection

Smallpox

United States, Puerto Rico

3

Subscribe